Welgene Biotech Co

Welgene Biotech Co Debt/EBITDA

The Total Debt to EBITDA Ratio of Welgene Biotech Co (6661.TWO) as of Oct 20, 2026 is 2,477.07. In the previous year, Total Debt to EBITDA Ratio was 21.50 — a change of 11,422.94% (higher).

Debt/EBITDA

2,477.07

YoY

11,422.94%

Last updated:

Total Debt to EBITDA Ratio of Welgene Biotech Co is 2025 2,477.07 . Total Debt to EBITDA Ratio of Welgene Biotech Co was 2024 21.50 . It decreases by 11,422.94% higher compared to the previous year.

The Welgene Biotech Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
0.37 TWD
Jan 1, 2019
1.08 TWD
Jan 1, 2020
0.76 TWD
Jan 1, 2021
1.96 TWD
Jan 1, 2022
3.08 TWD
Jan 1, 2023
-82.54 TWD
Jan 1, 2024
21.50 TWD
Jan 1, 2025
2,477.07 TWD
The Welgene Biotech Co Debt/EBITDA history
YEARDebt/EBITDAYoY
2,477.07+11,422.94%
21.50-126.04%
-82.54-2,778.46%
3.08+57.33%
1.96+157.92%
0.76-29.71%
1.08+195.19%
0.37-73.18%
1.36-60.64%
3.47+143.33%
1.42-2.86%
1.47—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Welgene Biotech Co Stock analysis

What does Welgene Biotech Co do? Welgene Biotech Co Ltd provides biotechnology services such as genetic testing, molecular diagnosis, and bioinformatics support to universities, hospitals, and pharmaceutical companies in Taipei City, Taiwan. The company specializes in DNA microarray, Next Generation Sequencing, and real-time quantitative PCR technologies, operating through two segments: Biotechnology Testing and Equipment Trading. Listed on 23 October 2017, it serves the local market with a focus on health care innovation. Welgene Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Welgene Biotech Co stock

Total Debt to EBITDA Ratio of Welgene Biotech Co is 2,477.07 in 2025.

Total Debt to EBITDA Ratio of Welgene Biotech Co changed from 21.50 to 2,477.07, representing a 11,422.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Welgene Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Welgene Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Welgene Biotech Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Welgene Biotech Co